Medanta

Gurugram, India Founded: 2004 • Age: 22 yrs Listed
Chain of multi-super specialty healthcare hospitals
Request Access
Report Incorrect Data
Page last updated

About Medanta

Medanta is a publicly listed company based in Gurugram (India) founded in 2004 by Sunil Sachdeva and Naresh Trehan. Chain of multi-super specialty healthcare hospitals. Medanta has raised $104.7 million across 4 funding rounds from investors including Avenue Capital Group, Punj Lloyd Group and Anant Investments. The company has 12,240 employees. Medanta was last valued at $546.32 million in December 2013. Its chief executive, as recorded, is Pankaj Prakash Sahni. Its website medanta.org draws about 1.6 million monthly visits. Its Indian entity Global Health Limited reported revenue of ₹4,528 Cr. Its focus areas include Hospital Chains and Multispecialty Hospital Chains. Its competitors include Fortis Healthcare, Ujala Cygnus and Narayana Health; 2 of its 3 listed competitors have raised funding.

Company details

Medanta was founded in 2004 and is headquartered in Gurugram, India, within the healthcare sector. A network of multi-super specialty hospitals is managed, with focus on cardiac surgery, liver and kidney transplants, robotic procedures in cardiology, urology, neurology, neurosciences, paediatrics, orthopaedics, and gynecology. Advanced cancer treatments are delivered alongside services including online doctor consultations, appointment booking, pharmacy home delivery, home care, radiology, air ambulance, health checkups, and laboratory testing.

  • Headquarters Gurugram, India
  • Employees 12,240
  • Founders Sunil Sachdeva, Naresh Trehan
  • Stage Public
  • Sectors
    Healthcare
  • Website category Health
  • Email
    ••••••••
  • Phone
    •••• ••••
  • Website medanta.org
  • Social LinkedIn X Facebook Instagram YouTube
  • Legal Name Global Health Limited
Operational Areas
Healthcare → Hospitals & Clinical Care
Key Metrics
  • Market Cap
    ₹37,366 Cr

    MEDANTA · NSE

  • Share Price
    ₹1,387.60

    -0.15% today

  • Revenue
    ₹4,410 Cr

    FY 2025-26 · +19.4% YoY

  • EBITDA
    ₹909 Cr

    Margin 20.6%

  • Net Profit
    ₹557 Cr

    FY 2025-26 · +7.5% YoY

  • P/E (TTM)
    58.2x

    P/B 8.7x

  • ROE
    15.1%

    ROCE 16.8%

  • Debt / Equity
    0.26

    Interest cover 13.1x

  • Total Equity Funding
    $104.7M (USD)

    in 4 rounds

  • Latest Funding Round
    $5.27M (USD), Private Equity Round

    Dec 2013

  • Investors
    Avenue Capital Group

    & 4 more

  • Employee Count
    12,240

Apps and channels of Medanta

Medanta publishes 2 mobile apps with over 500K+ downloads; its YouTube channel Medanta has 3.08M subscribers and 30 videos.

Medanta eCLINIC - Patient App
Google Play Medical Everyone Free
Developer: Medanta
View on Google Play
Medanta eCLINIC
App Store Medical 12+
Developer: Medanta Hospitals
View on App Store
Medanta
YouTube 3.08M subscribers 30 videos Howto & Style
Open channel

Videos from Medanta

The most watched videos on Medanta's YouTube channel, Medanta (3.08M subscribers). Click a video to play it here.

Banno ki Rasm | A Tradition of Self-Breast Examination | An Initiative by Medanta
130.7K views
3 minutes. 3 steps. Once a month | Self Breast Examination | Medanta
98.4K views
The Healthy Heart Podcast | Medanta Noida
20.7K views
High Blood Pressure: What You Need to Know | Heartline Podcast | Medanta Noida
20.2K views

More on Medanta.

Funding Insights of Medanta

Medanta has successfully raised a total of $104.7M across 4 strategic funding rounds. The most recent funding activity was a Private Equity Round of $5.27 million completed in December 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $104.7M
  • Total Rounds 4
  • Last Round Private Equity Round — $5.27M
  • First Round $5.73M

    (Feb 2006)

  • Investors Count 5

All 4 funding rounds of Medanta with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Dec 2013$5.27MPrivate Equity Round$546.32M–
Anant Investments
Jun 2012$12.47MPrivate Equity Round$302.25MPunj Lloyd Group
Naresh Trehan
Mar 2006$81.23MPrivate Equity Round$•••••Avenue Capital Group
Punj Lloyd Group
Feb 2006$5.73MPrivate Equity Round$•••••–
Naresh Trehan and Associates, Naresh Trehan
Valuation history
DateValuationStage
Dec 2013$546.32M••••••••
Jun 2012$302.25M••••••••
Mar 2006$•••••••••••••
Feb 2006$•••••••••••••
Premium access

Full valuation and stage history of Medanta

Every valuation point, the growth-stage changes (minicorn, soonicorn, unicorn) and the dates behind them require an active premium plan.

  • All valuation points
  • Stage changes
  • Dates
  • Exports

Verified entity values are shown only after access is granted.

Last known valuation $546.32M (Dec 2013). 5 investors in total: 4 institutional and 1 angel.

Investors in Medanta

Medanta has secured backing from 5 investors, including institutional, angel, and venture fund investors. Prominent investors backing the company include Avenue Capital Group, Punj Lloyd Group and Anant Investments.

All
Venture Fund
Institutional
Angel
InvestorDescriptionFounded YearDomainLocation
Avenue Capital Group
Diversified investments in distressed debt and securities are managed globally.
1995avenuecapital.comNew York, United States
Anant Investments
Stock broking firm offering trading in equities and derivatives on NSE and BSE.
anantinvestments.com
Punj Lloyd Group
EPC services in energy and infrastructure are delivered internationally.
1982punjlloydgroup.comGurugram, India
Naresh Trehan and Associates

Naresh Trehan

Renowned cardiac surgeon, founder of Medanta, active angel investor in healthcare
unknown_6f44e46562d840088
Premium access

Investor details for Medanta

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Global Health Limited (Medanta)

Global Health Limited is the primary company behind Medanta. The boards of the 3 registered companies of Medanta currently have 11 directors; the longest-serving is Sunil Sachdeva, appointed in 2004. 22 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Sunil Sachdeva
DIN 00012115
Director13 Aug 200422 yrs 2 moGlobal Health Limited, Medanta Holdings Private Limited, Global Health Patliputra Private Limited
Naresh Trehan
DIN 00012148
Managing Director01 Jun 200719 yrs 5 moGlobal Health Limited, Medanta Holdings Private Limited, Global Health Patliputra Private Limited
Ravi Kant Jaipuria
DIN 00003668
Director09 Nov 20169 yrs 11 moGlobal Health Limited, Medanta Holdings Private Limited
Praveen Mahajan
DIN 07138514
Director29 Oct 20206 yrsGlobal Health Limited, Medanta Holdings Private Limited, Global Health Patliputra Private Limited
Rajan Bharti Mittal
DIN 00028016
Director28 Jul 20215 yrs 3 moGlobal Health Limited
Ravi Gupta
DIN 00023487
Director28 Jul 20215 yrs 3 moGlobal Health Limited
Hari Shanker Bhartia
DIN 00010499
Director31 Jul 20215 yrs 3 moGlobal Health Limited
Vikram Singh Mehta
DIN 00041197
Director31 Jul 20215 yrs 3 moGlobal Health Limited
Ravi Shankar Singh
DIN 07614032
Manager01 Jan 20224 yrs 10 moGlobal Health Patliputra Private Limited
Pankaj Prakash Sahni
DIN 07132999
Whole-time director01 Jan 20233 yrs 10 moGlobal Health Limited, Medanta Holdings Private Limited, Global Health Patliputra Private Limited
Shonan Purie Trehan
DIN 07078955
Director13 Mar 20267 moGlobal Health Limited

People of Medanta

3 people are tracked at Medanta (3 in leadership); the tracked headcount is 12,240.

NameRoleGroup
Sunil Sachdeva
Co-FounderLeadership
Naresh Trehan
Co-Founder & ChairmanLeadership
Pankaj Prakash Sahni
CEOLeadership
Premium access

Complete people profiles for Medanta

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Medanta

Medanta is a publicly listed company on the NSE with ticker symbol MEDANTA in India, operating in the Health services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date16 Nov 2022
  • Listed onBSE: 543654 · NSE: MEDANTA
  • Listed entityGlobal Health Limited
  • Exchange sectorHealth services
  • ISININE474Q01031
  • Share price₹1,280.00 (-0.02% on the day) · 2026-10-14
  • Market capitalisation₹34,447 Cr
  • Price to earnings61.9
  • EPS (diluted, trailing year)₹20.68
  • Dividend yield0.04%
  • Volume (last session)119,827

Financials of Medanta

Exchange-reported figures of Global Health Limited, the listed company behind Medanta (NSE: MEDANTA).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹4,410 Cr
+19.4% YoY
EBITDA
₹909 Cr
+8.7% YoY
Profit After Tax
₹557 Cr
+7.5% YoY
Net Worth
₹3,962 Cr
+17.0% YoY
Total Assets
₹5,341 Cr
+25.9% YoY
Total Debt
₹1,190 Cr
+65.8% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue4,4103,6923,2752,7102,1671,4471,500
Revenue growth+19.4%+12.7%+20.9%+25.0%+49.8%-3.6%-
EBITDA909836809636458197192
EBITDA margin+20.6%+22.7%+24.7%+23.5%+21.1%+13.6%+12.8%
Profit before tax71564762744928132.4863.87
Net profit55751847832719628.9336.35
Net profit margin+12.6%+14.0%+14.6%+12.1%+9.0%+2.0%+2.4%
EPS (₹)20.7117.9217.8112.167.755.817.36
Balance sheet
Total assets5,3414,2423,8343,6642,8322,3922,354
Net worth3,9623,3862,9062,4281,6161,3821,350
Total debt1,1907188021,1221,109931929
Cash & bank1,1301,1221,1751,278512289250
Net working capital1,1111,0091,0631,146498200174
Cash flow
Cash from operations714624612645311242175
Cash from investing(1,089)(721)(441)(342)(421)(239)(87.07)
Cash from financing272(97.23)(514)346160(80.72)(0.88)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue1,4691,3041,1591,1211,0991,031931943
Revenue growth (YoY)+33.6%+26.5%+24.5%+18.8%+14.9%+19.7%--
Other income23.6222.1636.7421.7435.7120.4622.9316.02
EBITDA370287244181231247175238
EBITDA margin+25.2%+22.0%+21.0%+16.1%+21.0%+23.9%+18.8%+25.2%
Depreciation70.8068.9866.5261.1949.7345.1149.2548.45
Interest28.0926.6826.7121.5117.1113.7915.0316.28
Profit before tax295213187120200208133189
Tax75.6856.0245.6324.7541.4149.1632.0646.21
Net profit21915714295.03158159101143
EPS (₹)8.205.905.353.545.895.913.775.32
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue3,7093,2042,9751,9741,7651,2271,472
Revenue growth+15.8%+7.7%+50.7%+11.8%+43.8%-16.6%-
EBITDA744723753422381173218
EBITDA margin+20.1%+22.6%+25.3%+21.4%+21.6%+14.1%+14.8%
Profit before tax65062365935229684.43131
Net profit49649848626421956.70103
Net profit margin+13.4%+15.6%+16.3%+13.4%+12.4%+4.6%+7.0%
EPS (₹)18.4717.1818.119.828.6411.5520.82
Balance sheet
Total assets4,8493,9673,5842,8532,1231,7701,690
Net worth4,0133,4983,0372,4891,7401,4841,423
Total debt68333742428830822818.52
Cash & bank1,0761,0531,1371,145441255219
Net working capital1,0689791,0601,073478223176
Cash flow
Cash from operations573528559431235201193
Cash from investing(931)(638)(519)(257)(313)(250)(45.34)
Cash from financing264(94.49)(379)40497.59(36.67)(55.64)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue1,2081,079961940926882803812
Revenue growth (YoY)+30.4%+22.3%+19.7%+15.7%+39.4%+44.3%--
Other income25.8924.0635.8124.6638.7942.7325.6719.47
Total expenses918849767801734688658611
EBITDA290230193139193195145202
EBITDA margin+24.0%+21.3%+20.1%+14.8%+20.8%+22.1%+18.1%+24.8%
Depreciation56.1554.6052.2147.8637.4333.4137.9837.35
Interest17.0715.8913.4613.088.885.667.108.46
Profit before tax243183163103185198126175
Tax61.8145.8139.3522.9844.8546.2932.4843.89

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 06 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue1,4691,3041,1591,1211,0991,031931943
Revenue growth (YoY)+33.6%+26.5%+24.5%+18.8%+14.9%+19.7%--
Other income23.6222.1636.7421.7435.7120.4622.9316.02
EBITDA370287244181231247175238
EBITDA margin+25.2%+22.0%+21.0%+16.1%+21.0%+23.9%+18.8%+25.2%
Depreciation70.8068.9866.5261.1949.7345.1149.2548.45
Interest28.0926.6826.7121.5117.1113.7915.0316.28
Profit before tax295213187120200208133189
Tax75.6856.0245.6324.7541.4149.1632.0646.21
Net profit21915714295.03158159101143
EPS (₹)8.205.905.353.545.895.913.775.32
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue4,4103,6923,2752,7102,1671,4471,500
Revenue growth+19.4%+12.7%+20.9%+25.0%+49.8%-3.6%-
Other income11878.9574.6649.2938.5231.4243.85
Total expenses3,5012,8562,4662,0741,7091,2501,309
Employee cost1,096825735636568466539
EBITDA909836809636458197192
EBITDA margin+20.6%+22.7%+24.7%+23.5%+21.1%+13.6%+12.8%
Depreciation223194173150130123115
Interest90.0574.3583.7886.3386.3272.6456.56
Profit before tax71564762744928132.4863.87
Tax16116614912384.363.6627.54
Net profit55751847832719628.9336.35
Net profit margin+12.6%+14.0%+14.6%+12.1%+9.0%+2.0%+2.4%
EPS (₹)20.7117.9217.8112.167.755.817.36
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital53.7453.7253.7053.6450.6449.5949.35
Reserves & surplus3,9083,3332,8522,3751,5651,3001,268
Shareholders' funds (net worth)3,9623,3862,9062,4281,6161,3821,350
Minority interest22.711.10(0.03)0.000.000.000.00
Secured loans631276310754783568552
Unsecured loans559442492368326363377
Total debt1,1907188021,1221,109931929
Total liabilities5,3414,2423,8343,6642,8322,3922,354
Assets
Gross block5,0473,5783,1462,8772,4582,1732,141
Net block3,7952,5142,2362,0501,7761,6161,703
Capital work in progress132533388327439464382
Investments2.552.710.050.050.050.050.00
Inventories78.9867.1466.8560.3753.3939.7638.52
Sundry debtors411292215194180134149
Cash & bank balances1,1301,1221,1751,278512289250
Loans & advances54.5351.7951.2946.8166.3339.4440.81
Total current assets1,6751,5331,5091,579812502479
Total current liabilities564525446433314302305
Net working capital1,1111,0091,0631,146498200174
Total assets5,3414,2423,8343,6642,8322,3922,354
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash23042576711969.4714860.45
Net cash from operating activities714624612645311242175
Net cash from investing activities(1,089)(721)(441)(342)(421)(239)(87.07)
Net cash from financing activities272(97.23)(514)346160(80.72)(0.88)
Net change in cash(103)(194)(343)64849.97(78.11)87.12
Closing cash1,1301,1221,1751,278512289250
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+19.4%+12.7%+20.9%+25.0%+49.8%-3.6%-
EBITDA growth+8.7%+3.4%+27.1%+38.9%+132.6%+2.8%-
PBT growth+10.5%+3.2%+39.6%+60.1%+763.8%-49.2%-23.3%
Net income growth+7.5%+8.6%+46.2%+66.6%+577.5%-20.4%-
Revenue CAGR (3Y)+17.6%+19.4%+31.3%+21.8%+14.2%+2.5%+2.8%
EBITDA CAGR (3Y)+12.7%+22.2%+60.2%+49.2%+38.5%+16.2%-14.0%
Profitability & leverage
Net income margin+12.6%+13.0%+14.6%+12.0%+9.1%+2.0%+2.4%
Return on capital employed+16.8%+17.9%+19.0%+16.5%+14.1%+4.4%+5.4%
Return on net worth+15.1%+15.3%+17.9%+16.1%+13.1%+2.1%+2.8%
Debt / equity0.260.240.360.550.680.680.65
Long-term debt / equity0.240.200.300.490.610.640.61
Interest cover13.1111.5713.1717.7526.2998.5673.86
Efficiency & per share
Fixed asset turnover1.021.101.091.020.940.670.82
Inventory turnover60.3755.1151.4947.6446.5336.9648.55
Debtors turnover12.5514.5616.0014.4813.8110.239.58
EPS (₹)20.7117.9217.8112.167.755.817.36
Dividend per share (₹)0.500.000.000.000.000.000.00
Book value per share (₹)147.44126.08108.2290.5463.82272.22266.90
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue1,2081,079961940926882803812
Revenue growth (YoY)+30.4%+22.3%+19.7%+15.7%+39.4%+44.3%--
Other income25.8924.0635.8124.6638.7942.7325.6719.47
Total expenses918849767801734688658611
EBITDA290230193139193195145202
EBITDA margin+24.0%+21.3%+20.1%+14.8%+20.8%+22.1%+18.1%+24.8%
Depreciation56.1554.6052.2147.8637.4333.4137.9837.35
Interest17.0715.8913.4613.088.885.667.108.46
Profit before tax243183163103185198126175
Tax61.8145.8139.3522.9844.8546.2932.4843.89
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue3,7093,2042,9751,9741,7651,2271,472
Revenue growth+15.8%+7.7%+50.7%+11.8%+43.8%-16.6%-
Other income12690.8190.5947.5935.0428.3543.54
Total expenses2,9652,4822,2221,5521,3841,0541,254
Employee cost989746679533495416522
EBITDA744723753422381173218
EBITDA margin+20.1%+22.6%+25.3%+21.4%+21.6%+14.1%+14.8%
Depreciation17115013486.0987.1787.6498.57
Interest49.8240.6750.7831.8232.8329.2032.54
Profit before tax65062365935229684.43131
Tax15316217288.4677.0427.1428.18
Net profit49649848626421956.70103
Net profit margin+13.4%+15.6%+16.3%+13.4%+12.4%+4.6%+7.0%
EPS (₹)18.4717.1818.119.828.6411.5520.82
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital53.7453.7253.7053.6450.6449.5981.85
Reserves & surplus3,9593,4442,9832,4351,6891,4021,341
Shareholders' funds (net worth)4,0133,4983,0372,4891,7401,4841,423
Secured loans45811417166.4599.860.9618.08
Unsecured loans2252232532212082270.44
Total debt68333742428830822818.52
Total liabilities4,8493,9673,5842,8532,1231,7701,690
Assets
Gross block4,0092,8232,4911,4721,4101,3541,350
Net block2,9031,8611,645810827851929
Capital work in progress12045828074.946.424.163.47
Investments389366362765734626500
Inventories50.9049.0055.3542.2140.0231.6932.26
Sundry debtors387292214173173130148
Cash & bank balances1,0761,0531,1371,145441255219
Loans & advances56.2459.3953.6437.7861.7138.9836.32
Total current assets1,5701,4531,4601,398716455436
Total current liabilities503474400325238233260
Net working capital1,0689791,0601,073478223176
Total assets4,8493,9673,5842,8532,1231,7701,690
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash19039573465.3145.3113239.98
Net cash from operating activities573528559431235201193
Net cash from investing activities(931)(638)(519)(257)(313)(250)(45.34)
Net cash from financing activities264(94.49)(379)40497.59(36.67)(55.64)
Net change in cash(94.16)(205)(339)57720.01(86.25)91.58
Closing cash1,0761,0531,1371,145441255219
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+15.8%+7.7%+50.7%+11.8%+43.8%-16.6%-
EBITDA growth+3.0%-4.0%+78.4%+10.8%+120.2%-20.9%-
PBT growth+4.3%-5.4%+87.3%+18.9%+250.4%-35.5%+35.7%
Net income growth-0.6%+2.6%+84.2%+20.7%+285.5%-44.8%-
Revenue CAGR (3Y)+23.4%+22.0%+34.3%+10.3%+7.0%-3.0%+4.9%
EBITDA CAGR (3Y)+20.8%+23.8%+63.3%+24.5%+38.4%+10.0%+22.6%
Profitability & leverage
Net income margin+13.4%+14.4%+16.4%+13.3%+12.4%+4.7%+7.0%
Return on capital employed+15.9%+17.6%+22.1%+15.4%+16.9%+6.6%+10.3%
Return on net worth+13.2%+14.1%+17.6%+12.5%+13.6%+4.0%+7.7%
Debt / equity0.140.120.130.140.170.080.06
Long-term debt / equity0.130.090.100.110.140.070.05
Interest cover8.697.108.209.4711.1834.2427.13
Efficiency & per share
Fixed asset turnover1.091.211.501.371.280.911.16
Inventory turnover74.2661.4160.9848.0049.2238.3953.00
Debtors turnover10.9412.6815.3711.4011.658.829.42
EPS (₹)18.4717.1818.119.828.6411.5520.82
Dividend per share (₹)0.500.000.000.000.000.000.00
Book value per share (₹)149.34130.22113.1192.8068.70292.65281.74

Timeline of Medanta

5 dated milestones of Medanta across 18 years, from founding to its latest funding, stage changes and deals.

  1. Founded Medanta is founded.
  2. Funding First funding round of $5.7M.
  3. Milestone Reaches Minicorn status.
  4. Funding Latest funding round, Private Equity Round, of $5.3M.
  5. IPO Lists on the stock exchange (IPO).

Competitors of Medanta

Medanta has 3 listed competitors in our database, 2 of them funded. They include Fortis Healthcare, Ujala Cygnus and Narayana Health.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
Fortis Healthcare
fortishealthcare.com1996Gurugram, India1,565
Multi-specialty hospital services are provided across India by Fortis Healthcare.
Ujala Cygnus
ujalacygnus.com2011Delhi, India$36.74M2,084
A chain of multi-specialty hospitals is operated in India.
Narayana Health
narayanahealth.org2000Bengaluru, India$148.2M8,145
A chain of multi-specialty hospitals is operated in India.
Premium access

Detailed competitors of Medanta

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Medanta

The website of Medanta (medanta.org) receives about 1.6M visits a month and ranks #36,821 among all websites worldwide, #905 in Health.

  • Monthly visits
    1.6M

    ▲ 7.8% vs previous month

  • Unique visitors
    807.8K

    per month

  • Global rank
    #36,821

    among all websites

  • Category rank
    #905

    Health · Health

Similar websites

Websites whose visitors overlap most with Medanta. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
Max Healthcare
maxhealthcare.in
100%
1.5M#37,801View details
Fortis Healthcare
fortishealthcare.com
90%
808.8K#56,407View details
Artemis Hospital
artemishospitals.com
77%
56.5K#583,193View details
Paras Health
parashospitals.com
70%
389.5K#219,031View details
Sir Ganga Ram Hospital
sgrh.com
66%
144.8K#255,303View details
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
Premium access

All 40 similar websites and full traffic analytics for Medanta

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 40 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Hospitals & Clinical Care

3 companies that operate in the same segment as Medanta (Hospitals & Clinical Care) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Cloudnine
Maternity, childcare, and fertility services are delivered via hospital chains.
2007Bengaluru, Karnataka, IndiaUSD 204.87 MUSD 140.46 M4,459
HCG
Chain of oncology hospitals
1989Bengaluru, Karnataka, IndiaUSD 36.59 MUSD 270.51 M321
KIMS Hospitals
Multispeciality secondary and tertiary care is provided by hospital chains.
1999Secunderabad, Telangana, IndiaUSD 62.46 MUSD 416.2 M6,490
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Medanta

MEDANTA: Q2 REVENUE 14.7B RUPEES VS 10.99B (YOY)
Exchange Update • 4 days ago
MEDANTA: Q2 CONS NET PROFIT 2.19B RUPEES VS 1.58B (YOY)
Exchange Update • 4 days ago
MEDANTA: Q2 EBITDA 3.7B RUPEES VS 2.31B (YOY); Q2 EBITDA MARGIN 25.19% VS 21.01% (YOY)
Exchange Update • 4 days ago
Medanta operator Global Health buys Ghaziabad land for Rs 166 cr to build 350-bed hospital - The Economic Times
Economic Times • 1 month ago
Global Health Ltd: Receives 10,560.36 Sq. Meters Of Land For ₹165.82 Crores To Build A 350+ Bedded Hospital, Pending Approvals.
Exchange Update • 1 month ago
Global Health: Plans Analyst And Investor Meeting On September 25
Exchange Update • 1 month ago
Global Health: Investec on Global Health Initiates Buy with Target Price of ₹1,730 as the company is scaling beyond its core, ARPOB growth is expected at mid-to-high single digits, beds could double over five years with most additions post-FY29E, and revenue/EBITDA are forecast to grow at 16%/23% CAGR over FY26–29.
Exchange Update • 1 month ago
Buy Global Health; target of Rs 1750: Prabhudas Lilladher
Moneycontrol • 2 months ago
Global Health Shares Surge 2.01%, Trading at Rs 1,443.60
Moneycontrol • 2 months ago
Global Health Shares Rise 2% to Rs 1,421.40; Displays Strong Annual and Quarterly Financial Growth
Moneycontrol • 2 months ago
Premium access

Complete news archive for Medanta

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Medanta

Medanta was founded in 2004 and raised its 1st funding round 2 years after it was founded.

Medanta is headquartered in Gurugram, India. It is registered at Gurugram, Haryana, India.

Pankaj Prakash Sahni is the CEO of Medanta, as recorded in our data.

Medanta is a funded company, having raised a total of $104.7M across 4 funding rounds to date. The company's 1st funding round was a Private Equity Round of $5.73M, raised on Feb 2006.

Medanta has 12,240 employees.

The primary company behind Medanta, Global Health Limited, reported revenue of ₹4,528 Cr for FY 2026, up 19% year on year.

Medanta was founded in 2004 and is headquartered in Gurugram, India, within the healthcare sector. A network of multi-super specialty hospitals is managed, with focus on cardiac surgery, liver and kidney transplants, robotic procedures in cardiology, urology, neurology, neurosciences, paediatrics, orthopaedics, and gynecology. Advanced cancer treatments are delivered alongside services including online doctor consultations, appointment booking, pharmacy home delivery, home care, radiology, air ambulance, health checkups, and laboratory testing.

Medanta's top competitors include Fortis Healthcare, Ujala Cygnus and Narayana Health.

Yes, Medanta is publicly traded on NSE under the ticker symbol MEDANTA.

Medanta has 5 investors. Key investors include Avenue Capital Group, Punj Lloyd Group, Anant Investments, Naresh Trehan, and Naresh Trehan and Associates.

The valuation of Medanta is $546.32M as of Dec 2013.

Medanta is associated with 3 legal entities: Global Health Limited, Medanta Holdings Private Limited, Global Health Patliputra Private Limited.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available